Stay in Touch
To keep in touch, please sign up to the Milltrust Ventures Newsletter for our latest news and insights.
We hope that you and your family are healthy and safely getting through these uncertain times.
Please join us at 12:30pm BST on Thursday 16th of April for a special live Milltrust International Zoom Webinar on:
COVID-19 and The Future of Healthcare
The COVID-19 pandemic is savaging global populations and economies. More than ever, clinicians, scientists and planners need to come together to share and exchange best practices, ideas and experiences that will help to improve treatment and advance the search for and development of a vaccine.
Conference Call Details:
Date: Thursday, April 16, 2020
Time: 12:30pm British Standard Time
7:30pm Singapore Time/Hong Kong Time
7:30am Eastern US Time
We look forward to welcoming you to the discussion.
Join Zoom Meeting
Zoom Meeting Link: https://zoom.us/j/97790485114?pwd=Vk5NU2ZEQldRUnIzVG5WanIvVFBGUT09
Meeting ID: 977 9048 5114
A diagnostic company in Milltrust's British Innovation Fund, Attomarker has invented a new, simple to use, point-of-care blood testing device that can perform multiple tests from a single pinprick of blood in approximately five minutes. Currently assessing a multiplex test for COVID-19 which allows a rapid test for antibodies in the patient’s blood to five surface antigens and simultaneous measurement of the inflammatory biomarker, C- reactive protein. The results of each individual test will be available in approximately ten minutes. Testing has been underway at St Thomas’s NHS Hospital in London and progress to date has been highly encouraging. Alongside this work, the company is also in discussions with a global healthcare foundation to prepare a tuberculosis and polio testing pilot proposal. The company is looking to raise an additional £5m from its ongoing Series A round. Nigel Clarke is Chairman of Attomarker and serves as chair of the General Pharmaceutical Council (GPhC).
MyDoc, South Asia’s leading telemedicine service aims to bring primary care to patients where as many as 400 million persons have no access to a doctor. It has commenced a 6 country roll-out into the Philippines, Thailand, Malaysia, Vietnam and Indonesia notably under the aegis of the insurance companies Prudential and Aetna. Wavemaker and UST Global have invested and we are seeking to close a convertible round of 2 million USD ahead of a 15-20 million USD B round in the coming months. Given the current environment, the prospects for remote medicine are more compelling than ever. Dr Vas Metupalle trained as an MD at King’s London (Guys & St Thomas’s)
Vaccitech is a spin-out company from the University of Oxford's Jenner Institute, one of the oldest and most renowned vaccine research centres in the world. Vaccitech is a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID). A COVID-19 vaccine continues on track in collaboration with Vaccitech's colleagues at Oxford. Vaccitech is currently going through a fund raise.
Griff Williams, has primary responsibility for advising Milltrust International LLP, the investment manager, on portfolios investing in Australasia, and the British Innovation Fund which has over 70 underlying early-stage investments in the United Kingdom and follows a strategy which involves working with underlying investee companies to secure capital and business opportunity. The British Innovation Fund performed strongly in the year to 31 December 2019, up circa 24%, with its portfolio companies well placed to continue to progress in 2020.
Simon Hopkins is a successful entrepreneur and investment professional. He has been a senior figure in the international investment management industry for more than two decades. Milltrust is dedicated to sustainability & impact investing, focusing on the great existential challenges of our time including improving livelihoods, tackling climate change, feeding the world and improving health. Mr Hopkins serves as Chairman of the British Innovation Fund, a UK University Venture Fund and is a member of the NUS Medicine International Council (NIC).
FOR PROFESSIONAL / QUALIFIED INVESTORS ONLY – NOT FOR PUBLIC DISTRIBUTION
This material is a marketing communication
Statements attributed to an individual represent the opinions of that individual as of the date published and may not necessarily reflect the view of Milltrust International LLP or its affiliates. Milltrust International LLP uses reasonable efforts to obtain information from third-party sources which it believes to be reliable, Milltrust International LLP makes no representation or warranty as to the accuracy, reliability or completeness of the information. This communication is strictly private and confidential and is issued by Milltrust International LLP, incorporated in the United Kingdom, which is authorised and regulated by the Financial Conduct Authority. Milltrust International LLP has its registered office at 5 Market Yard Mews, 194-204 Bermondsey Street, London, SE1 3TQ, United Kingdom and is a subsidiary of Milltrust International Group (Singapore) Pte Ltd. None of the investment products mentioned herein are regulated collective investment schemes for the purposes of the UK Financial Services and Markets Act 2000. The promotion of such products and the distribution of this document are, accordingly, restricted by law. Most of the protections provided by the UK regulatory system and compensation under the UK’s Financial Services Compensation Scheme will not be available. The investments described herein are only available to investors permitted to invest in the prospectus of the fund and are not available to private investors. The nature of the fund investments carries certain risks and the Fund may utilise investment techniques which may carry additional risk. The value of investments and the income from them may fall as well as rise and is not guaranteed. Past performance is not a reliable indicator of future performance. This document contains forward-looking statements which are correct as at the date of this document. Such statements involve known and unknown risks, uncertainties and other important factors that could cause actual results, performance or projections to be materially different from future results. Any investment in the funds mentioned above should be based on the full details contained in the relevant prospectus and supplements which are available from www.milltrust.com. Notice to US investors: the shares of Milltrust International Managed Investments ICAV and Milltrust International Investments SPC have not been registered under the 1933 Securities Act or under the 1940 Act; however the company takes advantage of the 3[C]7 exemption and shares are available to 3[C](1) US qualified purchasers and those qualifying under Reg D distribution activity in the US is undertaken by Silverleaf Partners LLC, a registered broker-dealer based in New York.
Milltrust International LLP
6 Stratton Street
London W1J 8LD
Tel: +44 (0)20 8123 8316
Email: [email protected]